Madhusudana S N, Anand N P, Shamsundar R
National Institute of Mental Health and Neurosciences, PB No. 2900, Hosur Road, Bangalore 560029, Karnataka, India.
Natl Med J India. 2001 May-Jun;14(3):145-7.
Post-exposure prophylaxis for rabies with cell culture vaccines by the conventional intramuscular regimen is very expensive. The World Health Organization has advocated two cost-effective intradermal regimens with cell culture vaccines for use in developing countries. We evaluated these two regimens--the 2-site and the 8-site regimens--in terms of immunogenicity, safety and tolerance in people with category I exposure to rabies.
Eighty-two subjects who had mild category I exposure to rabies were immunized using a purified chick embryo cell vaccine. The first regimen given to 43 subjects, consisted of intradermal administration of 0.2 ml of vaccine at 2 sites on days 0, 3 and 7 and at one site on days 28 and 90. The second regimen, given to 39 subjects, consisted of intradermal administration of 0.1 ml of vaccine at 8 sites on day 0, at 4 sites on day 7 and at one site on days 28 and 90. The mouse neutralization test was used to estimate titres of rabies neutralizing antibody in these subjects on different days after vaccination. The subjects were followed up for 1 year.
Both regimens produced adequate neutralizing antibody titres from day 14 onwards, though the second regimen produced a more rapid antibody response and significantly higher titres (p < 0.001) on all days tested. There were minimal side-effects and both regimens were well tolerated.
Both the 2-site and 8-site intradermal regimens with purified chick embryo cell vaccine produce adequate levels of neutralizing antibodies but the 8-site regimen appears to be more immunogenic. The feasibility of using these cost-effective regimens in routine practice needs to be further evaluated under the field conditions prevalent in India.
采用传统肌内注射方案用细胞培养疫苗进行狂犬病暴露后预防费用高昂。世界卫生组织提倡在发展中国家使用两种具有成本效益的细胞培养疫苗皮内注射方案。我们针对I级狂犬病暴露者,从免疫原性、安全性和耐受性方面对这两种方案——2部位和8部位方案——进行了评估。
82名轻度I级狂犬病暴露者使用纯化鸡胚细胞疫苗进行免疫。给予43名受试者的第一种方案为在第0、3和7天于2个部位皮内注射0.2 ml疫苗,在第28和90天于1个部位注射。给予39名受试者的第二种方案为在第0天于8个部位皮内注射0.1 ml疫苗,在第7天于4个部位注射,在第28和90天于1个部位注射。采用小鼠中和试验来估计这些受试者在接种疫苗后不同时间的狂犬病中和抗体滴度。对受试者进行了1年的随访。
两种方案从第14天起均产生了足够的中和抗体滴度,不过第二种方案产生的抗体反应更快,且在所有检测日的滴度均显著更高(p < 0.001)。副作用极小,两种方案耐受性均良好。
纯化鸡胚细胞疫苗的2部位和8部位皮内注射方案均能产生足够水平的中和抗体,但8部位方案似乎免疫原性更强。在印度普遍存在的现场条件下,在常规实践中使用这些具有成本效益的方案的可行性需要进一步评估。